Hao Ou Bo: Net profit of 23.2 million yuan in 2025, the company's allergy products have been expanded to multiple series

Recently, Hao Ou Bo announced its 2025 annual report. The company’s operating revenue was 398 million yuan, a year-on-year decrease of 0.98%; net profit attributable to shareholders was 23.2 million yuan, a decrease of 36.96% year-on-year; net profit after non-recurring gains and losses attributable to shareholders was 14.72 million yuan, down 58.97% year-on-year; net operating cash flow was 72.94 million yuan, down 27.94% year-on-year; EPS (fully diluted) was 0.3655 yuan.

In its 2025 business operations, the company mainly focused on the in vitro diagnostics industry within the biomedical manufacturing sector, specializing in testing for allergic diseases and autoimmune diseases. During the reporting period, the company’s allergy products expanded to multiple series, covering 78 types of IgE allergens and 81 types of food-specific IgG allergens, and obtained several medical device registration certificates, further enhancing market competitiveness. Although the company’s overall revenue declined, it maintained profitability. Management mentioned that due to macroeconomic factors and changes in tax policies, product sales experienced a slight decline. Additionally, the company continued to increase efforts in promoting desensitization drugs in Hainan Free Trade Port and the Guangdong-Hong Kong-Macao Greater Bay Area. These markets are still in the cultivation stage, and the release of operational benefits has some lag. The company also maintained stable R&D investment to further promote technological innovation and market expansion of its products.

(Hao Ou Bo Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical